Inovio receives advanced therapy medicinal product certificate from european medicines agency for quality and non-clinical data for lead candidate ino-3107

Data reviewed complies with standards that would be  used to evaluate an eu marketing authorization application plymouth meeting, pa. , july 25, 2024 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that the european medicines agency's committee for advanced therapies (cat) has certified the quality and non-clinical data for ino-3107, inovio's lead candidate for the treatment of recurrent respiratory papillomatosis (rrp).
INO Ratings Summary
INO Quant Ranking